home / stock / xbit / xbit news

XBIT News and Press, XBiotech Inc. From 05/22/23

Stock Information
Company Name: XBiotech Inc.
Stock Symbol: XBIT
Market: NASDAQ
Website: xbiotech.com
Menu
XBIT XBIT Quote XBIT Short XBIT News XBIT Articles XBIT Message Board
Get XBIT Alerts

News, Short Squeeze, Breakout and More Instantly...
XBIT - FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis. The randomized, d...
XBIT - XBiotech, Impel top healthcare gainers; Intercept, Agile among losers

2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...

XBIT - XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common share...

XBIT - XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is being developed as a novel treatment ...
XBIT - XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix(TM) Therapy for Colorectal Cancer

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated ...

XBIT - XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

AUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combinatio...

XBIT - OCN, NVIV and XBIT among mid-day movers

Gainers: Statera Biopharma (STAB) +132%. SQZ Biotechnologies (SQZ) +35%. RCM Technologies (RCMT) +24%. Integrated Media Technology (IMTE) +21%. Ocwen Financial (OCN) +21%. Pitney Bowes (PBI) +20%. Allego (ALLG) +18%. PTC (PTC) +16%. LSI Industries (LYTS) +16%. XBiotech (XBIT) +...
XBIT - XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix(TM) in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Can

AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé (ANSM)] approved the laun...

XBIT - J&J to record $610M impairment charge from terminating development of therapy

Johnson & Johnson (NYSE:JNJ) said that it will record a $610M impairment charge in Q1 2022 as a result of ending development of the R&D asset bermekimab for atopic dermatitis. J&J acquired the rights to bermekimab from XBiotech (NASDAQ:XBIT) in FY 2020. J&J said it is still pu...

XBIT - XBiotech in antibody manufacturing deal with J&J unit Janssen

XBiotech (XBIT -2.6%) will manufacture Johnson & Johnson (JNJ +0.2%) division Janssen Research & Development products, including the monoclonal antibody Xilonix (bermekimab). Xilonix was sold to Janssen by XBiotech in December 2019. That out-licensing deal, which allows Janssen to dev...
Previous 10 Next 10